Announcement
28.02.2012

List of NeuroSearch announcements from January 2011 to February 2012

In accordance with section 27b of Consolidated Act about Securities Trading
etc., we hereby issue a complete list of NeuroSearch announcements from January
2011 to February 2012. All announcements are available under the IR section of
the company's website: www.neurosearch.com.


Date No. Title
--------------------------------------------------------------------------------
10.01.2011 01-11 ATP, AES and SUPP’s ownership in NeuroSearch has been reduced
to less than 10%
--------------------------------------------------------------------------------
11.01.2011 02-11 NeuroSearch announces a restructuring of the company to
support and strengthen strategic focus
--------------------------------------------------------------------------------
23.02.2011 03-11 NeuroSearch A/S – Annual General Meeting
--------------------------------------------------------------------------------
10.03.2011 04-11 NeuroSearch A/S – Financial statements and release of Annual
Report 2010
--------------------------------------------------------------------------------
10.03.2011 05-11 List of NeuroSearch announcements in 2010 and in January -
March 2011
--------------------------------------------------------------------------------
22.03.2011 06-11 Luxor Capital Group’s ownership in NeuroSearch has been
increased to more than 5%
--------------------------------------------------------------------------------
23.03.2011 07-11 NeuroSearch provides an update on the development plan for
Huntexil® in the treatment of Huntington's disease following
the End of Phase II meeting with the FDA
--------------------------------------------------------------------------------
28.03.2011 08-11 Notice convening Annual General Meeting of NeuroSearch A/S
--------------------------------------------------------------------------------
04.04.2011 09-11 NeuroSearch announces that the first patient has enrolled in
the Open HART safety extension study with Huntexil®
--------------------------------------------------------------------------------
27.04.2011 10-11 NeuroSearch A/S – Interim report for Q1 2011
--------------------------------------------------------------------------------
27.04.2011 11-11 Report on Annual General Meeting held in NeuroSearch A/S
--------------------------------------------------------------------------------
03.05.2011 12-11 NeuroSearch announces that Beckman Coulter becomes co-owner
of Atonomics to support the development of products for
local diagnostics based on the company's unique
Atolyzer®-platform
--------------------------------------------------------------------------------
16.05.2011 13-11 NeuroSearch extends the R&D alliance with Janssen
--------------------------------------------------------------------------------
17.05.2011 14-11 Luxor Capital Group’s ownership in NeuroSearch has been
increased to more than 10%
--------------------------------------------------------------------------------
24.05.2011 15-11 NeuroSearch reports on scientific advice from the EMA on the
clinical development programme for Huntexil®
--------------------------------------------------------------------------------
26.05.2011 16-11 NeuroSearch reports on scientific advice received from the
FDA and EMA concerning the clinical development programme
for tesofensine
--------------------------------------------------------------------------------
30.06.2011 17-11 NeuroSearch updates on the clinical development programme for
Huntexil®
--------------------------------------------------------------------------------
06.07.2011 18-11 NeuroSearch concludes agreement with Biolin Scientific
regarding the sale of Sophion Bioscience
--------------------------------------------------------------------------------
19.08.2011 19-11 Release date for the NeuroSearch H1 interim report
--------------------------------------------------------------------------------
25.08.2011 20-11 NeuroSearch A/S – H1 Report 2011
--------------------------------------------------------------------------------
15.09.2011 21-11 NeuroSearch attended the World Congress on Huntington's
Disease
--------------------------------------------------------------------------------
27.09.2011 22-11 NeuroSearch provides update on the Huntexil® development
programme and plans a comprehensive restructuring of the
company’s operations
--------------------------------------------------------------------------------
06.10.2011 23-11 Major shareholder announcement / Porter Orlin LLC
--------------------------------------------------------------------------------
25.10.2011 24-11 NeuroSearch announces changes in management
--------------------------------------------------------------------------------
08.11.2011 25-11 NeuroSearch publishes the MermaiHD study in The Lancet
Neurology
--------------------------------------------------------------------------------
10.11.2011 26-11 NeuroSearch – Release date for Q3 report 2011
--------------------------------------------------------------------------------
17.11.2011 27-11 NeuroSearch A/S – Q3 report 2011
--------------------------------------------------------------------------------
09.12.2011 28-11 NeuroSearch – Financial calendar for 2012
--------------------------------------------------------------------------------
15.12.2011 29-11 NeuroSearch research creates a basis for the establishment of
new biotech company named Acesion Pharma
--------------------------------------------------------------------------------
16.12.2011 30-11 Leading NeuroSearch employees establish new research and
development company named Aniona
--------------------------------------------------------------------------------
16.12.2011 31-11 Major shareholder announcement / Porter Orlin LLC
--------------------------------------------------------------------------------
23.12.2011 32-11 NeuroSearch announces changes to the A. Carlsson Research AB
share purchase agreement
--------------------------------------------------------------------------------
26.01.2012 01-12 Notice convening Extraordinary General Meeting in NeuroSearch
A/S
--------------------------------------------------------------------------------
10.02.2012 02-12 NeuroSearch announces a change to the date of the Annual
General Meeting 2012
--------------------------------------------------------------------------------
10.02.2012 03-12 NeuroSearch – Financial calendar for 2012
--------------------------------------------------------------------------------
20.02.2012 04-12 Report on Extraordinary General Meeting in NeuroSearch A/S
--------------------------------------------------------------------------------
22.02.2012 05-12 Release date for the financial statements 2011 for
NeuroSearch A/S and subsequent telephone conference
--------------------------------------------------------------------------------
28.02.2012 06-12 NeuroSearch announces the company's Annual Report 2011
--------------------------------------------------------------------------------

Patrik Dahlen
CEO

Contact person:
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097

About NeuroSearch
NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on
NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is to complete the development and
subsequently to market Huntexil®, a unique drug in clinical Phase III for the
treatment of the motor symptoms of Huntington’s disease.
As a consequence of the restructuring of NeuroSearch that was announced 27
September 2011, the company also has a portfolio of assets for outlicensing or
divestment.

Fonds.07-12 - Company announcements in 2011-2012 - uk.pdf